- Home
- CCEC vs COGT Comparison
CCEC vs COGT Comparison
Compare CCEC & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- COGT
- Stock Information
- Founded
- CCEC 2007
- COGT 2014
- Country
- CCEC Greece
- COGT United States
- Employees
- CCEC N/A
- COGT N/A
- Industry
- CCEC Marine Transportation
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- CCEC Consumer Discretionary
- COGT Health Care
- Exchange
- CCEC Nasdaq
- COGT Nasdaq
- Market Cap
- CCEC 1.1B
- COGT 984.0M
- IPO Year
- CCEC 2007
- COGT 2018
- Fundamental
- Price
- CCEC $18.79
- COGT $8.90
- Analyst Decision
- CCEC Buy
- COGT Buy
- Analyst Count
- CCEC 1
- COGT 6
- Target Price
- CCEC $22.00
- COGT $14.67
- AVG Volume (30 Days)
- CCEC 23.4K
- COGT 1.3M
- Earning Date
- CCEC 11-08-2024
- COGT 11-12-2024
- Dividend Yield
- CCEC 3.19%
- COGT N/A
- EPS Growth
- CCEC N/A
- COGT N/A
- EPS
- CCEC 0.85
- COGT N/A
- Revenue
- CCEC $447,305,000.00
- COGT N/A
- Revenue This Year
- CCEC N/A
- COGT N/A
- Revenue Next Year
- CCEC N/A
- COGT N/A
- P/E Ratio
- CCEC $76.15
- COGT N/A
- Revenue Growth
- CCEC 29.66
- COGT N/A
- 52 Week Low
- CCEC $13.10
- COGT $3.67
- 52 Week High
- CCEC $20.26
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- CCEC N/A
- COGT 28.97
- Support Level
- CCEC N/A
- COGT $9.97
- Resistance Level
- CCEC N/A
- COGT $11.16
- Average True Range (ATR)
- CCEC 0.00
- COGT 0.78
- MACD
- CCEC 0.00
- COGT -0.25
- Stochastic Oscillator
- CCEC 0.00
- COGT 2.02
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the leading platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.